REGENXBIO Inc. filed an 8-K with the SEC on September 23, 2026, disclosing that it and the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics and Catalent, Inc. to resolve all patent infringement litigation related to the gene therapy product ELEVIDYS.

Key Highlights

  • Settlement payment: Sarepta will pay $39.0 million to REGENXBIO within 10 days of the effective date of the Settlement Agreement.
  • Patents at issue: The litigation concerned U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274, related to Sarepta's manufacture, use, offer to sell, and sale of SRP-9001 (ELEVIDYS).
  • Litigation termination: All ongoing patent litigation regarding the Patents-in-Suit will be terminated with prejudice following the settlement.
  • Covenant not to sue: REGENXBIO and UPenn agreed to release all current infringement claims and will not sue for future claims relating to any Sarepta gene therapy product using an AAVrh74-based capsid, including ELEVIDYS, as to the Patents-in-Suit and U.S. Patent No. 9,198,984.
  • Scope limitation: The covenant not to sue does not extend to patents or patent applications covering other aspects of gene therapy products beyond the existing form of ELEVIDYS or the AAVrh74-based capsid sequence.

REGENXBIO and UPenn Resolve ELEVIDYS Patent Litigation with Sarepta

According to the filing, REGENXBIO Inc. (NASDAQ:RGNX) and The Trustees of the University of Pennsylvania entered into the Settlement Agreement with Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC, and Catalent, Inc. on September 23, 2026. The agreement resolves all patent infringement litigation alleging infringement of two patents - U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274 - in connection with Sarepta's manufacture, use, offer to sell, and sale of SRP-9001, marketed in the U.S. as ELEVIDYS.

The filing discloses that Sarepta will make a payment of $39.0 million to REGENXBIO within 10 days of the effective date of the Settlement Agreement. Following that payment, the parties will terminate with prejudice all ongoing patent litigation regarding the Patents-in-Suit. As part of the arrangement, REGENXBIO and UPenn will release all current infringement claims and covenant not to sue Sarepta for future claims relating to any Sarepta gene therapy product using an AAVrh74-based capsid, as to the Patents-in-Suit and U.S. Patent No. 9,198,984, and related patents and patent applications.

The filing further states that REGENXBIO agreed not to sue Sarepta or its affiliates, licensees, or commercial partners over any Company patents or patent applications covering the existing form of ELEVIDYS or the AAVrh74-based capsid sequence. However, according to the filing, this agreement "does not extend to patents or patent applications that cover other aspects of gene therapy products." The company noted it intends to file a copy of the Settlement Agreement with its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.

What Was Disclosed

REGENXBIO disclosed a Settlement Agreement with Sarepta Therapeutics and Catalent, Inc. to end all patent litigation over ELEVIDYS, with Sarepta paying $39.0 million to REGENXBIO and the parties agreeing to mutual release and covenant provisions related to AAVrh74-based gene therapy products.